Company Long-Term Loans and Borrowings: Lumos Pharma Corp (LUMO)

Public company logo of Lumos Pharma Corp (LUMO)

The price chart for Lumos Pharma, Inc. (LUMO) reflects the dynamics of an asset whose value is currently determined by medical trial outcomes rather than market pricing, and stands at 0.01. The business minimizes risks by utilizing its platform to combat various endocrine disorders. Furthermore, the development of therapy for somatotropin deficiency provides the firm with a reliable, multi-year cash generator through lifelong support for pediatric patients.

LUMO Lumos Pharma, Inc. Company Long-Term Debts (07/04/2022 - 12/21/2024)

Summary analytical data breakdowns for Lumos Pharma Corp (LUMO)

- market price and analyst price targets:
Stock Price lumos-pharma.com|LUMO - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Lumos Pharma|LUMO - Total Company Value
- book capitalization information:
Accounting Value per Share Lumos Pharma|LUMO - Book Capitalization|Market Capitalization to Book Value Ratio lumos-pharma.com|LUMO - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Lumos Pharma, Inc.|LUMO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Lumos Therapeutics|LUMO - Company Aggregate Debts|Debts to Book Value Lumos Pharma|LUMO - Company Long-Term Liabilities|Amount of Current Liabilities Lumos Pharma|Quick Ratio lumos-pharma.com
- earnings and multiples data:
LUMO - Net Profit
Summary company analytics:Lumos Pharma, Inc.
Brand item of Lumos Pharma, Inc.

This metric captures the total volume of credit obligations for Lumos Pharma, Inc. (LUMO) with maturities exceeding twelve months. The growth of this metric reflects a debt load that requires comparison with operating liquidity to assess solvency. Amid geopolitical instability and disruptions in raw material supply chains, borrowings become a survival tool. By analyzing the changes in the corporation's long-term loans and borrowings, an investor identifies the extent to which development depends on external financing. The stability of this indicator confirms the fundamental resilience of the business.

Competitor analysis for Lumos Pharma, Inc.

Company Long-Term Debts ascendispharma.com ASND|MDGL - Company Long-Term Debt|Company Long-Term Loans and Borrowings CORT (Corcept Therapeutics Inc.)|Rhythm Pharmaceuticals Inc (RYTM) - Company Long-Term Debt|Company Long-Term Liabilities Akero Corp|MTSR (Metsera Inc) - Company Long-Term Debts|Company Long-Term Debts moonlaketx.com|Company Long-Term Liabilities CRNX (Crinetics)|NAMS (NewAmsterdam Pharma Company) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Soleno SLNO|FOLD - Company Long-Term Liabilities|89bio, Inc. - Company Long-Term Debts|Long-Term Debt agios.com|GPCR (Structure Therapeutics Inc.) - Company Long-Term Liabilities|MDXG: Amount of Long-Term Liabilities|RZLT (Rezolute Corp) - Company Long-Term Debts|Company Long-Term Debts Lexicon Corp|Company Long-Term Debts MBX|Company Long-Term Debt ALT (altimmune.com)|Company Long-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Long-Term Debt|BIOA - Company Long-Term Debt|BMEA: Company Long-Term Debt|QNCX: Company Long-Term Debts|GUTS - Long-Term Debt Volume|Company Long-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Long-Term Debt Volume|Company Long-Term Debt Pluri Inc. (PLUR)|Company Long-Term Liabilities synlogictx.com SYBX|Company Long-Term Debt Lipocine Inc. LPCN|Matinas BioPharma Holdings, Inc. - Company Long-Term Debt|SPRB: Company Long-Term Liabilities|GLTO - Company Long-Term Debts|Carmell Corp (CTCX) - Company Long-Term Debt|Company Long-Term Liabilities Organovo Corp|Company Long-Term Debt Radius Recycling, Inc.